Instruction for use: Actastav

Active substance Mesalazine

ATX Code A07EC02 Mesalazine

Pharmacological group

NSAIDs - Salicylic acid derivatives

Nosological classification (ICD-10)

K50 Crohn's disease [regional enteritis]

Crohn's disease, Crohn's disease with fistula, Granuloma of the intestine, Granulomatous enteritis, Crohn's disease, Regional ileitis, Terminal Ileitis, Enteritis regional

K51 Ulcerative colitis

Colitis acute ulcerative, Colitis ulcerative, Ulcerative-necrotic colitis, Colitis ulcerative-hemorrhagic nonspecific, Colitis ulcerative and trophic, Colitis ulcerative idiopathic, Colitis ulcerative nonspecific, Nonspecific ulcerative colitis, Proctocolitis ulcers, Hemorrhagic purulent rectoxitis, Rectoccolitis ulcerative-hemorrhagic

K52 Other noninfectious gastroenteritis and colitis

senile Bowel Syndrome, sigmoid, Gastroenteritis noninfectious, gastroenterocolitis, Colitis, Colitis non-dysenteric, Colitis noninfectious, Colitis is a chronic, Colitis is a chronic non-infectious, Local enteritis, sigmoid noninfectious, Chronic inflammatory bowel disease, Chronic inflammatory disease of the small intestine, Chronic enterocolitis, Chronic atrophic gastroenteritis, Chronic gastroenteritis, Chronic colitis, Chronic enterocolitis, Enteritis, non-infectious enteritis, Enterocolitis chronic noncommunicable, colon disease

K62 Other diseases of anus and rectum

Composition and form of release

1 tablet contains mesalazine 250 and 500 mg; in a package of 50 or 100 pcs .;

1 rectal suppository - 250 mg; in a package of 5 or 10 pcs.

pharmachologic effect

Pharmacological action - anti-inflammatory.

Pharmacokinetics

After taking the majority of the dose reaches the ileum and large intestine (absorption is negligible), where the active substance is released (the dragee is covered with a special coating that prevents absorption in the stomach and proximal part of the small intestine).

Indication

Nonspecific ulcerative colitis; Crohn's disease (prevention and treatment of exacerbations), colitis chronic; proctitis.

Contraindications

Hypersensitivity (including to derivatives of salicylic acid), severe violations of liver function, hemorrhagic diathesis.

pregnancy and lactation

Not recommended.

Side effects

Headache, weakness, bronchospasm, pseudo erythritis, methemoglobinemia, allergic reactions.

Interaction

Increases the toxicity of methotrexate, sulfonamides, furosemide, rifampicin, hypoglycemic effect of sulfonylurea derivatives and ulcerogenic effects of glucocorticoids.

Dosing and Administration

During exacerbations, inside - 0.5-1 g 3-4 times a day for 8-12 weeks; or rectally - 2 suppositories 3-4 times a day (ie, 1.5-2 g / day), in especially severe cases, the daily dose can be doubled. For the prevention of exacerbations - 0.25-0.5 g 3-4 times a day or 1 candle 3-4 times a day.

Precautionary measures

With prolonged therapy, regular blood and urine tests should be performed regularly.

storage Conditions

In a dry, cool place protected from light.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.